Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors

This study is to evaluate the safety, pharmacokinetics, and preliminary antitumor activity of TYK-00540 as monotherapy or combined with fulvestrant in advanced solid tumors.

Trial Details

NCT ID

NCT06950086

Phase

PHASE1 / PHASE2

Sponsor

TYK Medicines, Inc

Status

RECRUITING

Cancer Type

HER2 Negative Breast Cancer

Interventions

TYK-00540

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806
Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Age ≥18 years, gender requirements:
Monotherapy dose-escalation phase: No gender restriction.
Combination dose-selection phase: No gender restriction.
Monotherapy and combination expansion phases:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →